Read this patient information before you start taking velasof, and each time you get a refill, there may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.
Velasof is a prescription medicine used to treat adults with chronic (lasting for a long time) Hepatitis C Virus (HCV), genotype 1, 2, 3, 4, 5 or 6 infection,
Velasof contains active ingredients like sofosbuvir (400 mg) and velpatasvir (100 mg).
The film-coated tablet contains colors like indigo carmine aluminum lake, brilliant blue FCF aluminum lake & titanium dioxide IP.
The recommended dosage of velasof is one tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food. The treatment regimen and duration in patients with genotypes 1, 2, 3, 4, 5 or 6 HCV infection is mentioned in the below table.
|Patient Population||Recommended Treatment Regimen|
|Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A)||Velpatasvir/Sofosbuvir for 12 weeks|
|Patients with decompensated cirrhosis (Child-Pugh B and C)||Velpatasvir/Sofosbuvir+ribavirin for 12 weeks|
The combination of sofosbuvir and velpatasvir along with ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. Males and females who take sofosbuvir and velpatasvir combination with ribavirin should also read the ribavirin medication guide for important pregnancy, contraception and infertility information.
Slow Heart Rate (Bradycardia): Sofosbuvir and velpatasvir combination treatment may result in slowing of heart rate along with amiodarone, a medicine used to treat certain heart problems. Cardiac arrest is seen in patients when sofosbuvir is coadministered along with amiodarone. Patients with bradycardia must seek medical evaluation immediately. The other possible symptoms include,
The subject should be monitored for verification of toxicity, besides that, supportive measures should be taken. Hemodialysis can be effective in removing the sofosbuvir metabolites whereas it is unlikely for velpatasvir.
Keep sofosbuvir and velpatasvir combination and all medicines out of reach of children.